Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Aptevo Therapeutics Inc. Director's Dealing 2017

May 23, 2017

35422_dirs_2017-05-23_b035f547-29a3-484f-9def-6d7fa72e82ff.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Aptevo Therapeutics Inc. (APVO)
CIK: 0001671584
Period of Report: 2017-05-22

Reporting Person: White Marvin L (Director, President and CEO)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2017-05-22 Common Stock M 35643 Acquired 48504 Direct
2017-05-22 Common Stock M 17828 Acquired 66332 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2017-05-22 Restricted Stock Unit $ M 35643 Disposed Common Stock (35643) Direct
2017-05-22 Restricted Stock Unit $ M 17828 Disposed Common Stock (17828) Direct

Footnotes

F1: Each RSU converts into the Issuer's common stock on a one-for-one basis.

F2: The RSUs were originally issued by Emergent BioSolutions, Inc. ("Emergent") on May 21, 2015. As a result of the spin-off of the Issuer from Emergent effective on August 1, 2016 (the "Spin-off"), each RSU was adjusted and assumed by the Issuer. The RSUs vest in three equal annual installments beginning on the first anniversary of the grant date.

F3: The RSUs were originally issued by Emergent on May 22, 2014 and, as a result of the Spin-off, were adjusted and assumed by the Issuer. The RSUs fully vested on May 22, 2017.